Today: 19 April 2026
UOB stock price wobbles after JPMorgan downgrade as MAS review and earnings near
27 January 2026
2 mins read

UOB stock price wobbles after JPMorgan downgrade as MAS review and earnings near

Singapore, January 27, 2026, 14:50 (SGT) — Regular session.

United Overseas Bank Ltd (UOB) (SGX:U11) shares dipped 0.3% to S$38.40 by 2:48 pm in Singapore, underperforming its local peers as the market climbed. DBS Group advanced around 1.5%, and OCBC rose 1.3%, while the FTSE Straits Times Index gained about 1%. UOB is currently valued at roughly 11 times trailing earnings, with a dividend yield near 4.6%.

All eyes are on the Monetary Authority of Singapore’s policy review this Thursday. Most economists surveyed by Reuters predict no change to current settings. Edward Lee, chief economist at Standard Chartered, said there’s “no urgency to act” right now. But Bank of America economists warn MAS might tighten policy at this review if inflation shows signs of picking up. Instead of adjusting interest rates, MAS steers monetary conditions by managing the Singapore dollar within a trade-weighted policy band. Reuters

UOB is set to report its full-year 2025 financial results on Feb. 24, with the announcement coming before the market opens, according to an SGX filing. Investors will focus on any shifts in the bank’s approach to credit costs—the reserves for bad loans—and its fee income, following a turbulent year across the region.

The stock is still reacting after Monday’s drop in Singapore’s banking trio, which dragged the Straits Times Index down 0.6%. UOB took the biggest hit, closing Jan. 26 down 2.5% at S$38.50, reported.

On Jan. 25, JPMorgan downgraded UOB from “neutral” to “underweight,” keeping its target price steady at S$34, according to the Business Times. This followed a 5% jump in UOB shares on Jan. 23, when the stock closed at S$39.50 before starting to pull back. Meanwhile, Macquarie analyst Jayden Vantarakis upgraded UOB to “outperform,” setting a target of S$41 and pointing to wealth inflows driven by Singapore’s “safe-haven” status. The Business Times

Analysts Tay Wee Kuang and Lim Siew Khee at CGS International forecast UOB’s net profit for Q4 2025 to hit about S$1.28 billion, marking a 16.7% drop year-on-year. They linked this to a tougher comparison base following a one-off deferred tax expense in Q4 2024. The duo also pointed to softer wealth management and loan-related fees. Meanwhile, they expect credit costs to ease by 28 basis points from the previous quarter — with a basis point representing 0.01 percentage point. They warned of downside risks from a “weaker economic outlook for ASEAN” and potential extra provisioning tied to UOB’s exposure in Greater China’s commercial property sector. Asian Banking Finance

UOB moved on wholesale funding, pricing A$2 billion ($1.39 billion) of senior unsecured notes in two tranches, according to FinanceAsia. This move highlights the bank’s ability to tap offshore debt markets while broadening its funding sources.

The share price’s next move could hinge on whether UOB manages to steer clear of another surge in provisions and maintain lending margins amid shifting rates. In November, the bank projected its 2026 net interest margin—the gap between loan earnings and deposit costs—would drop to 1.75%-1.80%, following a hefty S$1.36 billion in credit allowances booked in Q3.

Markets will get a near-term cue on Jan. 29, when MAS releases its quarterly monetary policy statement. UOB’s associate economist Jester Koh said there’s “little urgency to act now,” though some analysts expect a possible hawkish shift. Attention for UOB shares then turns to Feb. 24, the date set for its FY25/4Q25 earnings report. The Straits Times

Stock Market Today

  • Nordea Bank Abp's Mixed Share Performance and Valuation Analysis
    April 18, 2026, 10:42 PM EDT. Nordea Bank Abp (HLSE:NDA FI) exhibits mixed returns with a negative year-to-date but a 51.1% total return over one year, showing strong long-term momentum. The bank's share price closed at €16.02, slightly below the €16.55 analyst target and a fair value estimate of €17.03, suggesting it may be undervalued. Nordea is investing heavily in digital technologies and cybersecurity, aiming to improve net margins and fee income. However, potential risks include Nordic housing market weakness and rising regulatory costs. Investors are advised to weigh both upside potential and downside risks before making decisions, considering broader financial sector comparisons and market conditions.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Wesfarmers shares jump 2.3% as Australia CPI looms — what to watch next on ASX
Previous Story

Wesfarmers shares jump 2.3% as Australia CPI looms — what to watch next on ASX

iFAST stock price jumps 4% as ShopeePay Money+ launch puts SGX:AIY back in focus
Next Story

iFAST stock price jumps 4% as ShopeePay Money+ launch puts SGX:AIY back in focus

Go toTop